ACRS – aclaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4/29
09:00 am
acrs
Medium
Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush.
4/28
02:05 pm
acrs
Low
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript [Seeking Alpha]
4/28
10:22 am
acrs
Low
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus [Yahoo! Finance]
4/28
07:32 am
acrs
Low
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
4/28
06:30 am
acrs
High
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
2/26/2026
06:58 am
ACRS
-7.8%
MISS
11/6/2025
06:59 am
ACRS
0.4%
BEAT
8/7/2025
06:59 am
ACRS
1.3%
IN-LINE
5/8/2025
06:50 am
ACRS
7.4%
BEAT
4/29
12:01 pm
Maintains
Outperform
Outperform
Wedbush
Low
1.4%
4/29
12:01 pm
Maintains
Outperform
Outperform
Wedbush
Low
1.4%
4/29
09:00 am
Reiterates
Outperform
Outperform
Wedbush
Medium
5.9%
4/29
09:00 am
Reiterates
Outperform
Outperform
Wedbush
Medium
5.9%
4/16
08:17 am
Initiates
Outperform
Oppenheimer
Medium
-5.0%
4/28
06:45 am
acrs
High
Form 8-K Aclaris Therapeutics, For: Apr 28
4/27
07:27 pm
acrs
Medium
Form 4 Aclaris Therapeutics, For: Apr 27 Filed by: Leonard Braden Michael
4/27
07:26 pm
acrs
Medium
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
4/23
07:48 am
acrs
Medium
Form ARS Aclaris Therapeutics, For: Dec 31
4/23
07:47 am
acrs
Medium
Form DEFA14A Aclaris Therapeutics,
Show more
Top News Gainers
9/16 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) 63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
Top News Decliners
6/26 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints -52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3